Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult : A Consensus Approach from the Trans-Atlantic RPS Working Group (vol 23, pg 3531, 2016)
Jack L. Ahlen, Sergio Sandrucci(University of Turin), Andrea J. MacNeill(University of British Columbia), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Vittorio Quagliuolo(Humanitas University), Angelo Paolo Dei Tos(University of Padua), Venu G. Pillarisetty(University of Washington), Kenneth Cardona(Emory University), Hans Gelderblom(Leiden University Medical Center), R. Antbacka, Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Rick L. Haas(Leiden University Medical Center), A. Italiano, Wilfried Hartmann, Jean‐Yves Blay(Université Claude Bernard Lyon 1), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Valerie P. Grignol(Ohio State University Hospital), Peter Hohenberger(University of Mannheim), Christina Messiou(Institute of Cancer Research), Antonino De Paoli(Centro di Riferimento Oncologico), Rolando F. Del Maestro(Artificial Intelligence in Medicine (Canada)), R.L. Jones, Giovanni Grignani(Candiolo Cancer Institute), Ian Judson(Erasmus Hospital), Carla Colombo(University of Milan), Nita Ahuja(Yale University), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Raphael E. Pollock(The Ohio State University), Brendan C. Dickson(Sinai Health System), A.J. Hayes, Robert J. Canter(Virginia Tech), Jens Jakob(Heidelberg University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Pierre Méeus(Centre Léon Bérard), Fritz C. Eilber(APLA Health), Sanjay P. Bagaria(WinnMed), Stefano Redaelli(Fondazione IRCCS Istituto Nazionale dei Tumori), John T. Mullen(Massachusetts General Hospital), Chris Fletcher, A Desai(Queen Elizabeth Hospital Birmingham), John M. Kane(Roswell Park Comprehensive Cancer Center), Elisabetta Pennacchioli(European Institute of Oncology), R. González, Guy Lahat(Tel Aviv University), Thomas Henzler, Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k